agency to sort of clarify that science and that's not existed in the past. So we're trying to set up some type of system or forum where we can do this internally within the agency and develop consistent policies and procedures for resolving these issues in the GMP area. Basically, we're looking to be able to have a dispute resolution process between regulated industry and the FDA and also between the components of FDA because there is a lack of consistency from center to center on how we will handle some of the scientific disputes.
483 communication. There has been a lot of concern on the part of industry about how we communicate observations on our 483, which is the form that's used during the inspection process. What we're planning on doing is honing the language to communicate deficiencies better, again to be more consistent. Right now in order to ensure that consistency, we're actually combining this particular working group, the working group that's looking at communications on 483 and through inspections in general, with the dispute resolution group. So those two groups are working together to try and ensure that industry is better informed of the observations, that the